|Bid||290.01 x 1000|
|Ask||302.00 x 800|
|Day's Range||290.72 - 297.29|
|52 Week Range||287.66 - 442.00|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||16.49|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||389.16|
TARRYTOWN, N.Y. , Aug. 15, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the Morgan Stanley 17th Annual Global Healthcare Conference at 8:10 a.m. ...
Is Regeneron Pharmaceuticals Holdings (REGN) a great pick from the value investor's perspective right now? Read on to know more.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) has received ample support from multiple catalysts this week. On Tuesday, the company announced FDA approval for its prefilled Eylea syringe. The good news ...
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 13) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) NextCure ...
Regeneron Pharmaceuticals, Inc. (REGN) today announced positive pivotal Phase 3 results for evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody, in patients with homozygous familial hypercholesterolemia (HoFH). Patients with HoFH have severely elevated levels of bad cholesterol (otherwise known as low-density lipoprotein cholesterol, or LDL cholesterol), and often experience early atherosclerotic disease, sometimes suffering cardiac events as early as their teenage years.
An experimental Ebola drug developed by Regeneron Pharmaceuticals has shown promising results. But Wall Street hasn’t rewarded the stock because of it.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) shares were trading higher Tuesday after Eylea, its product to treat retinal conditions, snagged another approval. What Happened Regeneron said Tuesday ahead ...
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
The 2 mg, single-dose, sterilized prefilled syringe provides physicians with a new way to administer EYLEA that requires fewer preparation steps compared to vials. Market supply of the EYLEA prefilled syringe is expected to be available to physicians and patients this year.
Two of four experimental Ebola drugs being tested in Congo seem to be saving lives, international health authorities announced Monday. The preliminary findings prompted an early halt to a major study on the drugs and a decision to prioritize their use in the African country, where a yearlong outbreak has killed more than 1,800 people. The early results mark “some very good news,” said Dr. Anthony Fauci of the U.S. National Institutes of Health, which helped fund the study.
Scientists are a step closer to being able to cure the deadly Ebola haemorrhagic fever after two experimental drugs showed survival rates of as much as 90% in a clinical trial in Congo. Two experimental drugs - an antibody cocktail called REGN-EB3 developed by Regeneron and a monoclonal antibody called mAb114 - will now be offered to all patients infected with the viral disease in an ongoing outbreak in the Democratic Republic of Congo (DRC).
Regeneron Pharmaceuticals Inc said on Monday its experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death, in a trial evaluating four treatments for infections caused by the deadly virus. The company said the trial was ended early because its therapy, REGN-EB3, elicited a "highly statistically significant result" compared to Mapp's ZMapp, which was considered a standard-of-care treatment.
ZMapp served as the control arm of the trial because it was considered the standard-of-care based on the previous PREVAIL II clinical trial. The independent data safety monitoring board decided to stop the trial after reviewing interim mortality data from 499 patients. "The Regeneron team worked tirelessly to discover, develop and produce REGN-EB3 in record time utilizing our VelocImmune®-based technologies," said Neil Stahl, Ph.D., Executive Vice President of Research and Development at Regeneron.
The drug developer's revenue growth was fueled by double-digit increases in medications that treat macular degeneration, eczema and asthma.